Too Few Visible Catalysts For Revance Push Guggenheim to The Sidelines By: Benzinga via Benzinga January 09, 2018 at 17:44 PM EST Revance Therapeutics Inc (NASDAQ: RVNC) announced interim Phase 2a results for RT002 in treating Plantar Fasciitis, which showed ... Read More >> Related Stocks: Revance Therapeutics